High molecular remission rate in high risk follicular lymphoma with sequential high-dose therapy and rituximab as purging in vivo

被引：0
|
作者：
Specchia, M. R. [1 ]
Pricolo, G. [1 ]
Casulli, F. [1 ]
Mazza, P. [1 ]
机构：
[1] SC Ematol Osped SG Moscati, Taranto, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：189 / 189
页数：1
相关论文
共 50 条
  • [1] A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma
    L Arcaini
    E Orlandi
    E P Alessandrino
    I Iacona
    E Brusamolino
    M Bonfichi
    P Bernasconi
    S Calatroni
    A Tenore
    F Montanari
    D Troletti
    C Pascutto
    M Regazzi
    M Lazzarino
    [J]. Bone Marrow Transplantation, 2004, 34 : 175 - 179
  • [2] A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma
    Arcaini, L
    Orlandi, E
    Alessandrino, EP
    Iacona, I
    Brusamolino, E
    Bonfichi, M
    Bernasconi, P
    Calatroni, S
    Tenore, A
    Montanari, F
    Troletti, D
    Pascutto, C
    Regazzi, M
    Lazzarino, M
    [J]. BONE MARROW TRANSPLANTATION, 2004, 34 (02) : 175 - 179
  • [3] Sequential high-dose therapy plus rituximab as in vivo purging agent in low grade lymphomas
    Mazza, P
    Prudenzano, A
    Pricolo, G
    Stani, L
    Maggi, A
    Amurri, B
    Palazzo, G
    Pisapia, G
    [J]. BONE MARROW TRANSPLANTATION, 2003, 31 : S72 - S72
  • [4] Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as hi vivo purging and to maintain re ion following high-dose therapy
    Pettengell, R.
    Schmitz, N.
    Gisselbrecht, C.
    Caballero, D.
    Colombat, P.
    Conde, E.
    Metzner, B.
    Walewski, J. A.
    Geisler, C.
    Goldstone, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] High-dose therapy for follicular lymphoma
    Freedman, A
    Friedberg, JW
    Gribben, J
    [J]. ONCOLOGY-NEW YORK, 2000, 14 (03): : 321 - +
  • [6] Effect of rituximab and/or high-dose therapy with autotransolant at time of relapse in patients with follicular lymphoma
    Coiffier, Bertrand
    Brice, Pauline
    Delarue, Richard
    Haioun, Corinne
    Souleau, Bertrand
    Mounier, Nicolas
    Feugier, Pierre
    Tilly, Herve
    Sebban, Catherine
    [J]. BLOOD, 2007, 110 (11) : 120A - 120A
  • [7] High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first remission
    Metzner, B
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2002, 178 (06) : 352 - 353
  • [8] High-dose therapy for follicular lymphoma revisited: Not if, but when?
    Lister, TA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) : 3894 - 3896
  • [9] High-dose sequential chemotherapy coupled with autologous PBSCT and in vivo purging with rituximab in patients with relapsed/refractory or high-risk B-cell NHL
    Oyan, B
    Koc, Y
    Ozdemir, E
    Kansu, E
    [J]. BONE MARROW TRANSPLANTATION, 2005, 35 : S385 - S385
  • [10] Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma
    Kang, T. Y.
    Rybicki, L. A.
    Bolwell, B. J.
    Thakkar, S. G.
    Brown, S.
    Dean, R.
    Sekeres, M. A.
    Advani, A.
    Sobecks, R.
    Kalaycio, M.
    Pohlman, B.
    Sweetenham, J. W.
    [J]. BONE MARROW TRANSPLANTATION, 2007, 40 (10) : 973 - 978
12345